Fulzos 250MG Injection (5ml) is a pharmaceutical formulation containing Fulvestrant, a potent estrogen receptor antagonist used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. This medication works by blocking the effects of estrogen, a hormone that can promote the growth of certain types of breast tumors. Fulzos is typically administered via intramuscular injection, allowing for effective absorption and action within the body. The composition of Fulzos includes 250mg of Fulvestrant in a 5ml solution, which is designed to be injected into the muscle, ensuring that the drug is delivered directly into the bloodstream for optimal therapeutic effect. This injection is crucial for patients who have experienced disease progression following anti-estrogen therapy, providing a targeted approach to managing their condition. The use of Fulzos is an essential part of a comprehensive treatment plan for breast cancer, helping to improve patient outcomes and quality of life.